Topics Engaged In
-
- Topic
- Voices
- Last Post
-
-
ASCO/NCCN guidlines now out
Started by:
in: Side-effect management
- 5
- October 14, 2018 at 5:40 am
-
New BRAF/MEK inhibitors coming to market
Started by:
- 7
- October 8, 2018 at 10:07 am
-
Adjuvant Nivolumab at 480 side effect
Started by:
in: Side-effect management
- 5
- September 30, 2018 at 6:29 pm
-
Nivolumab dosing and Medicare
Started by:
- 7
- July 23, 2018 at 4:02 pm
-
Pembro plus Epacadostat
Started by:
- 6
- June 11, 2018 at 2:29 pm
-
BRAF testing for adjuvant therapy
Started by:
- 6
- June 3, 2018 at 6:18 am
-
Adjuvant targeted therapy
Started by:
- 4
- May 11, 2018 at 9:44 pm
-
Adjuvant Immunotherapy in stage IIIA patients
Started by:
- 7
- May 5, 2018 at 8:59 pm
-
PET/CT scans
Started by:
- 7
- April 13, 2018 at 5:00 pm
-
Survivorship plans
Started by:
- 7
- March 29, 2018 at 9:39 pm
-
Opdivo dosing changes
Started by:
- 5
- March 29, 2018 at 9:25 pm
-
Infusion times
1
2
Started by:
- 8
- March 14, 2018 at 10:54 pm
-
Adjuvant Treatment with Targeted Therapy
Started by:
- 4
- February 23, 2018 at 5:43 pm
-
Reimbursement for infliximab
Started by:
- 6
- February 17, 2018 at 11:10 pm
-
Sugar and melanoma
Started by:
- 3
- January 31, 2018 at 8:43 pm
-
ASCO/NCCN guidlines now out